Go Pro
→ 60 years. Zero competitors. (From Behind the Markets) (Ad)tc pixel Free GRTX Stock Alerts

Galera Therapeutics (GRTX) Financials

Galera Therapeutics logo
$0.09 0.00 (0.00%)
As of 07/10/2026
Compare
Annual Income Statements for Galera Therapeutics

Annual Income Statements for Galera Therapeutics

This table shows Galera Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -59 -74 -81 -62 -59 -19 435
Consolidated Net Income / (Loss)		 -52 -74 -81 -62 -59 -19 149
Net Income / (Loss) Continuing Operations		 -52 -74 -81 -62 -59 -19 149
Total Pre-Tax Income 		-52 -74 -81 -62 -59 -19 149
Total Operating Income		 -51 -71 -73 -51 -49 -20 -2.54
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 51 71 73 51 49 20 2.54
Selling, General & Admin Expense		 8.36 16 21 20 23 11 5.69
Research & Development Expense		 42 55 52 31 24 6.99 0.35
Impairment Charge		 - - - - 0.00 3.14 0.00
Restructuring Charge		 - - - 0.00 2.31 0.00 0.00
Other Special Charges / (Income)		 - - - - 0.00 -0.98 -3.50
Total Other Income / (Expense), net		 -1.25 -3.68 -7.17 -11 -9.82 1.00 152
Interest Expense		 3.03 4.88 7.19 12 11 0.00 -151
Interest & Investment Income		 1.82 1.17 0.03 0.51 1.60 0.55 0.25
Other Income / (Expense), net		 -0.04 0.03 -0.00 -0.00 -0.00 0.45 0.29
Income Tax Expense		 -0.01 -0.02 0.00 0.07 0.00 -0.20 0.00
Basic Earnings per Share		 ($16.31) ($2.98) - ($2.30) ($1.33) ($343.23) $645.53
Weighted Average Basic Shares Outstanding		 3.63M 24.87M 25.79M 27.09M 44.55M 54.63M 98.62M
Diluted Earnings per Share		 ($16.31) ($2.98) - ($2.30) ($1.33) ($343.23) $645.53
Weighted Average Diluted Shares Outstanding		 3.63M 24.87M 25.79M 27.09M 44.55M 54.63M 98.62M
Weighted Average Basic & Diluted Shares Outstanding		 3.63M 24.87M 25.79M 27.09M 44.55M 75.46M 75.46M

Quarterly Income Statements for Galera Therapeutics

This table shows Galera Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -15 -5.59 -4.38 -4.06 -5.58 -5.16 -1.59 -1.08 -1.39 439 -1.61
Consolidated Net Income / (Loss)		 -15 -5.59 -4.38 -4.06 -5.58 -4.93 -1.59 -1.08 -1.39 153 -1.61
Net Income / (Loss) Continuing Operations		 -15 -5.59 -4.38 -4.06 -5.58 -4.93 -1.59 -1.08 -1.39 153 -1.61
Total Pre-Tax Income 		-15 -5.59 -4.38 -4.06 -5.78 -4.94 0.00 -1.08 -1.39 153 0.00
Total Operating Income		 -13 -5.18 -4.58 -4.21 -5.91 -5.47 -1.96 -1.14 -1.44 1.99 -1.66
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 13 5.18 4.58 4.21 5.91 5.47 1.96 1.14 1.44 -1.99 1.66
Selling, General & Admin Expense		 4.99 1.99 3.09 2.78 3.44 1.70 1.87 1.05 1.31 1.47 1.64
Research & Development Expense		 6.09 3.19 1.49 1.43 0.31 3.77 0.09 0.08 0.13 0.04 0.02
Impairment Charge		 0.00 - - - 3.14 - 0.00 - 0.00 - 0.00
Other Special Charges / (Income)		 0.00 - - - -0.98 - 0.00 - 0.00 - 0.00
Total Other Income / (Expense), net		 -1.68 -0.41 0.20 0.15 0.12 0.53 0.37 0.06 0.05 151 0.05
Interest & Investment Income		 0.41 0.30 0.20 0.15 0.13 0.08 0.08 0.06 0.05 0.06 0.05
Other Income / (Expense), net		 -0.00 - 0.00 0.00 -0.00 0.45 0.29 0.00 0.00 - 0.00
Income Tax Expense		 0.00 - - - -0.20 - 0.00 - 0.00 - 0.00
Basic Earnings per Share		 ($0.33) ($0.02) ($0.08) ($0.07) ($0.10) ($342.98) ($7.32) ($4.94) ($6.38) $656.86 ($7.38)
Weighted Average Basic Shares Outstanding		 45.48M 44.55M 54.39M 54.39M 54.39M 54.63M 98.62M 98.62M 98.62M 98.62M 98.62M
Diluted Earnings per Share		 ($0.33) ($0.02) ($0.08) ($0.07) ($0.10) ($342.98) ($7.32) ($4.94) ($6.38) $656.86 ($7.38)
Weighted Average Diluted Shares Outstanding		 45.48M 44.55M 54.39M 54.39M 54.39M 54.63M 98.62M 98.62M 98.62M 98.62M 98.62M
Weighted Average Basic & Diluted Shares Outstanding		 54.39M 44.55M 54.39M 54.39M 54.39M 75.46M 75.46M 75.46M 75.46M 75.46M 160.43M

Annual Cash Flow Statements for Galera Therapeutics

This table details how cash moves in and out of Galera Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 3.55 -2.48 3.99 -16 14 -9.97 -1.91
Net Cash From Operating Activities		 -47 -60 -68 -43 -45 -12 -6.05
Net Cash From Continuing Operating Activities		 -47 -60 -68 -43 -45 -12 -6.05
Net Income / (Loss) Continuing Operations		 -52 -74 -81 -62 -59 -19 149
Consolidated Net Income / (Loss)		 -52 -74 -81 -62 -59 -19 149
Depreciation Expense		 0.27 0.37 0.78 0.11 0.26 0.02 0.00
Non-Cash Adjustments To Reconcile Net Income		 5.66 10 14 19 17 9.12 -154
Changes in Operating Assets and Liabilities, net		 -0.66 3.90 -2.63 0.02 -2.93 -2.33 -0.67
Net Cash From Investing Activities		 -28 37 5.24 24 27 -0.05 3.50
Net Cash From Continuing Investing Activities		 -28 37 5.24 24 27 -0.05 3.50
Purchase of Investments		 -123 -68 -72 -60 -23 -0.05 0.00
Sale of Property, Plant & Equipment		 - - - - 0.00 0.00 0.00
Divestitures		 - - - - - 0.00 3.50
Net Cash From Financing Activities		 78 21 67 3.89 31 2.22 0.64
Net Cash From Continuing Financing Activities		 78 21 67 3.89 31 2.22 0.64
Issuance of Common Equity		 58 0.00 7.94 3.81 29 2.22 0.64
Other Financing Activities, net		 20 21 59 0.08 2.20 - 0.00

Quarterly Cash Flow Statements for Galera Therapeutics

This table details how cash moves in and out of Galera Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 0.08 -6.17 -4.79 -2.72 -2.29 -0.17 -1.60 -1.46 -0.76 1.90 -0.88
Net Cash From Operating Activities		 -13 -9.92 -4.79 -2.72 -2.30 -2.34 -2.24 -1.46 -0.76 -1.60 -0.88
Net Cash From Continuing Operating Activities		 -13 -9.92 -4.79 -2.72 -2.30 -2.34 -2.24 -1.46 -0.76 -1.60 -0.88
Net Income / (Loss) Continuing Operations		 -15 -5.59 -4.38 -4.06 -5.58 -4.93 -1.59 -1.08 -1.39 153 -1.61
Consolidated Net Income / (Loss)		 -15 -5.59 -4.38 -4.06 -5.58 -4.93 -1.59 -1.08 -1.39 153 -1.61
Depreciation Expense		 0.01 0.22 0.01 0.01 0.01 - 0.00 - - - 0.00
Non-Cash Adjustments To Reconcile Net Income		 3.48 1.89 0.88 0.72 3.74 3.79 -0.16 0.09 0.09 -154 0.08
Changes in Operating Assets and Liabilities, net		 -0.94 -6.44 -1.29 0.62 -0.46 -1.20 -0.49 -0.47 0.54 -0.25 0.65
Net Cash From Investing Activities		 10 3.98 0.00 - 0.00 -0.05 0.00 - - 3.50 0.00
Net Cash From Continuing Investing Activities		 10 3.98 0.00 - 0.00 -0.05 0.00 - - 3.50 0.00
Sale of Property, Plant & Equipment		 - - - - - - 0.00 - - - 0.00
Net Cash From Financing Activities		 2.13 -0.23 0.00 - - 2.22 0.64 - - - 0.00
Net Cash From Continuing Financing Activities		 2.13 -0.23 0.00 - - 2.22 0.64 - - - 0.00
Issuance of Common Equity		 1.93 -0.23 0.00 - - - 0.64 - - - 0.00

Annual Balance Sheets for Galera Therapeutics

This table presents Galera Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 88 123 84 83 44 26 10 7.20
Total Current Assets		 84 118 78 77 39 22 10 7.10
Cash & Equivalents		 15 18 16 20 4.27 18 8.29 6.38
Prepaid Expenses		 1.47 5.28 5.15 6.18 3.65 3.37 1.08 0.72
Plant, Property, & Equipment, net		 0.57 0.93 1.02 0.53 0.44 0.07 0.00 0.00
Total Noncurrent Assets		 3.64 4.87 5.15 5.39 5.06 4.44 0.10 0.10
Other Noncurrent Operating Assets		 0.50 1.73 2.01 2.25 1.92 1.30 0.10 0.10
Total Liabilities & Shareholders' Equity		 88 123 84 83 44 26 10 7.20
Total Liabilities		 27 54 78 141 153 157 154 0.65
Total Current Liabilities		 6.44 9.69 14 13 13 4.96 1.67 0.00
Accounts Payable		 3.87 3.95 5.15 5.04 3.58 1.38 1.28 0.27
Accrued Expenses		 2.58 5.45 8.58 7.63 9.75 3.45 0.39 0.38
Total Noncurrent Liabilities		 21 44 64 128 140 152 152 0.00
Commitments & Contingencies		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 166 - - - - - 4.37 2.58
Total Equity & Noncontrolling Interests		 -105 70 6.12 -58 -109 -131 -148 3.97
Total Preferred & Common Equity		 -105 70 6.12 -58 -109 -131 -148 3.97
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Total Common Equity		 -105 70 6.12 -58 -109 -131 -148 3.97
Common Stock		 0.00 231 242 258 269 306 308 311
Retained Earnings		 -105 -161 -236 -316 -378 -437 -456 -307

Quarterly Balance Sheets for Galera Therapeutics

This table presents Galera Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 38 20 16 8.90 7.66 6.05 5.00 6.16
Total Current Assets		 31 15 12 8.90 7.56 5.95 4.90 6.06
Cash & Equivalents		 24 13 11 8.46 6.69 5.23 4.47 5.50
Prepaid Expenses		 2.83 1.72 1.21 0.44 0.87 0.72 0.43 0.56
Plant, Property, & Equipment, net		 0.20 0.06 0.06 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 6.34 4.40 4.37 0.00 0.10 0.10 0.10 0.10
Other Noncurrent Operating Assets		 3.20 1.26 1.23 0.00 0.10 0.10 0.10 0.10
Total Liabilities & Shareholders' Equity		 38 20 16 8.90 7.66 6.05 5.00 6.16
Total Liabilities		 164 154 154 152 152 151 152 1.14
Total Current Liabilities		 13 2.01 2.13 0.91 0.98 0.35 0.60 0.00
Accounts Payable		 3.72 1.05 0.81 0.30 0.74 0.20 0.43 0.70
Accrued Expenses		 8.78 0.83 1.16 0.62 0.23 0.15 0.16 0.44
Total Noncurrent Liabilities		 152 152 152 151 151 151 151 0.00
Commitments & Contingencies		 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - - - - - 2.60 - 4.30
Total Equity & Noncontrolling Interests		 -127 -135 -138 -143 -144 -148 -147 0.73
Total Preferred & Common Equity		 -127 -135 -138 -143 -147 -148 -149 0.73
Preferred Stock		 0.00 0.00 0.00 0.00 2.86 - 2.58 0.00
Total Common Equity		 -127 -135 -138 -143 -147 -148 -149 0.73
Common Stock		 305 307 308 308 311 311 311 310
Retained Earnings		 -432 -442 -446 -451 -458 -459 -460 -309

Annual Metrics And Ratios for Galera Therapeutics

This table displays calculated financial ratios and metrics derived from Galera Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 24,807,789.00 24,951,352.00 26,438,767.00 28,500,066.00 54,392,170.00 54,392,170.00 75,462,390.00
DEI Adjusted Shares Outstanding		 24,807,789.00 24,951,352.00 26,438,767.00 28,500,066.00 54,392,170.00 54,392,170.00 75,462,390.00
DEI Earnings Per Adjusted Shares Outstanding		 -2.38 -2.97 -3.05 -2.18 -1.09 -0.35 5.76
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -39.03% -3.47% 29.59% 4.13% 59.81% 88.59%
EBIT Growth		 0.00% -39.02% -4.03% 30.18% 3.83% 59.98% 88.60%
NOPAT Growth		 0.00% -39.18% -3.99% 30.18% 3.84% 59.07% 81.99%
Net Income Growth		 0.00% -42.92% -8.51% 22.74% 5.05% 67.91% 886.25%
EPS Growth		 0.00% 81.73% 0.00% 0.00% 42.17% -25,706.77% 288.08%
Operating Cash Flow Growth		 0.00% -27.59% -14.14% 36.10% -3.27% 72.92% 50.19%
Free Cash Flow Firm Growth		 0.00% 0.00% 144.12% -314.90% -7.99% 55.84% -1,249.35%
Invested Capital Growth		 0.00% -56.71% -94.16% -9.17% -6.06% -1.77% 100.12%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 6.22% 1.69% 14.33% -0.30% 75.72%
EBIT Q/Q Growth		 0.00% 0.00% 5.71% 2.51% 13.98% 0.79% 75.72%
NOPAT Q/Q Growth		 0.00% 0.00% 5.71% 2.50% 13.98% -1.46% 63.69%
Net Income Q/Q Growth		 0.00% 0.00% 3.89% 0.99% 15.21% 3.34% 1,758.68%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 29.63% -127,022.22% 5,752.63%
Operating Cash Flow Q/Q Growth		 0.00% -2.01% -1.49% 7.46% 8.25% 38.42% 10.91%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 14.66% 2.49% 28.68% -1,990.50%
Invested Capital Q/Q Growth		 0.00% 0.00% 2.00% -0.41% 2.84% -0.29% 100.12%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.98% 99.98% 100.00% 99.89% 100.00% 98.94% 100.00%
Interest Burden Percent		 102.38% 105.25% 109.76% 121.60% 119.93% 97.19% -6,630.29%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -79.47% -196.02% 310.43% 74.43% 49.16% 13.79% -217.40%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -87,884.09%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 21.41% -196.02% 310.43% 74.43% 49.16% 14.01% -228.42%
Return on Equity Simple (ROE_SIMPLE)		 -74.60% -1,213.11% 138.84% 56.99% 45.04% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -35 -49 -51 -36 -34 -14 -2.54
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -14.69% -26.91% -40.66% -51.41% -98.94% -36.69% 2,067.53%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - 26.31% 9.53% -63.97%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -51 -71 -73 -51 -49 -20 -2.25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -50 -70 -73 -51 -49 -20 -2.25
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.69 41.59 0.00 0.00 0.00 0.00 3.60
Price to Tangible Book Value (P/TBV)		 0.72 85.40 0.00 0.00 0.00 0.00 3.60
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.03
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,040.78%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 59.67
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 4.24 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.04 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.61 -2.44 2.77 0.61 0.21 0.10 0.11
Leverage Ratio		 1.62 2.74 -3.23 -0.76 -0.29 -0.13 -0.13
Compound Leverage Factor		 1.66 2.88 -3.54 -0.93 -0.35 -0.13 8.36
Debt to Total Capital		 0.42% 3.74% -0.45% -0.04% -0.10% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.42% 3.74% -0.45% -0.04% -0.10% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% -3.04% 39.34%
Common Equity to Total Capital		 99.58% 96.26% 100.45% 100.04% 100.10% 103.04% 60.66%
Debt to EBITDA		 -0.01 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 2.22 1.03 0.98 0.62 0.37 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.01 0.00 -0.01 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 3.16 1.47 1.38 0.88 0.53 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -1.61 -3.82 -6.79 -15.02 -28.85 -68.67 -46.33
Noncontrolling Interest Sharing Ratio		 126.94% 0.00% 0.00% 0.00% 0.00% -1.59% -5.07%
Liquidity Ratios		 - - - - - - -
Current Ratio		 12.13 5.58 5.98 2.88 4.36 6.00 0.00
Quick Ratio		 11.58 5.21 5.51 2.36 3.68 4.98 0.00
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -25 11 -24 -26 -11 -155
Operating Cash Flow to CapEx		 -7,371.41% -13,027.79% -24,013.43% -173,704.00% -76,013.56% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -5.20 1.55 -2.08 -2.27 0.00 0.00
Operating Cash Flow to Interest Expense		 -15.39 -12.20 -9.45 -3.75 -3.93 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -15.60 -12.29 -9.49 -3.76 -3.93 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -42 -66 -129 -141 -149 -152 0.18
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -24 -63 -12 -8.53 -2.65 152
Enterprise Value (EV)		 -64 182 47 8.76 -12 4.00 11
Market Capitalization		 48 254 118 40 6.48 7.92 14
Book Value per Share		 $2.81 $0.25 ($2.19) ($3.83) ($2.41) ($2.72) $0.05
Tangible Book Value per Share		 $2.68 $0.12 ($2.31) ($3.94) ($2.47) ($2.72) $0.05
Total Capital		 70 6.36 -58 -109 -131 -144 6.55
Total Debt		 0.30 0.24 0.26 0.04 0.13 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -112 -73 -71 -32 -18 -8.29 -6.38
Capital Expenditures (CapEx)		 0.63 0.46 0.28 0.03 0.06 -0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.12 -8.58 -6.50 -6.45 -1.45 0.05 0.72
Debt-free Net Working Capital (DFNWC)		 108 64 65 25 17 8.34 7.10
Net Working Capital (NWC)		 108 64 64 25 17 8.34 7.10
Net Nonoperating Expense (NNE)		 16 25 29 26 25 4.85 -152
Net Nonoperating Obligations (NNO)		 -112 -73 -71 -32 -18 -8.29 -6.38
Total Depreciation and Amortization (D&A)		 0.27 0.37 0.78 0.11 0.26 0.02 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.98) ($3.12) $0.00 ($1.33) ($0.34) $645.53
Adjusted Weighted Average Basic Shares Outstanding		 0.00 24.98M 26.80M 42.83M 44.55M 54.63M 98.62M
Adjusted Diluted Earnings per Share		 $0.00 ($2.98) ($3.12) $0.00 ($1.33) ($0.34) $645.53
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 24.98M 26.80M 27.09M 44.55M 54.63M 98.62M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.98) ($3.12) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 24.87M 25.79M 27.09M 44.55M 75.46M 75.46M
Normalized Net Operating Profit after Tax (NOPAT)		 -35 -49 -51 -36 -33 -13 -4.23
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 -16.74 -14.45 -10.20 -4.43 -4.32 0.00 0.00
NOPAT to Interest Expense		 -11.71 -10.12 -7.14 -3.10 -3.02 0.00 0.00
EBIT Less CapEx to Interest Expense		 -16.95 -14.55 -10.24 -4.43 -4.32 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -11.92 -10.21 -7.18 -3.10 -3.03 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Galera Therapeutics

This table displays calculated financial ratios and metrics derived from Galera Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 43,928,666.00 54,392,170.00 54,392,170.00 54,392,170.00 54,392,170.00 54,392,170.00 75,462,390.00 75,462,390.00 75,462,390.00 75,462,390.00 75,462,390.00
DEI Adjusted Shares Outstanding		 43,928,666.00 54,392,170.00 54,392,170.00 54,392,170.00 54,392,170.00 54,392,170.00 75,462,390.00 75,462,390.00 75,462,390.00 75,462,390.00 75,462,390.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.34 -0.10 -0.08 -0.07 -0.10 -0.09 -0.02 -0.01 -0.02 5.82 -0.02
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -3.50% 62.30% 67.05% 74.97% 55.88% -1.15% 63.46% 73.00% 75.68% 139.70% 0.84%
EBIT Growth		 -3.38% 60.74% 67.03% 74.96% 55.89% 3.05% 63.54% 73.03% 75.70% 139.70% 0.84%
NOPAT Growth		 -3.38% 60.74% 67.03% 74.96% 55.90% -5.60% 57.11% 73.03% 75.69% 152.06% 15.69%
Net Income Growth		 5.99% 65.49% 75.26% 80.38% 62.97% 11.74% 63.66% 73.55% 75.13% 3,204.93% -0.88%
EPS Growth		 45.00% 96.55% 84.00% 85.42% 69.70% -1,714,800.00% -9,050.00% -6,957.14% -6,280.00% 291.52% -0.82%
Operating Cash Flow Growth		 -35.95% 28.90% 58.93% 74.72% 81.65% 76.41% 53.29% 46.41% 67.06% 31.68% 60.90%
Free Cash Flow Firm Growth		 990.30% 89.15% -137.09% -239.12% -253.96% -124.02% 263.15% 128.01% 77.71% -12,654.16% -5,656.06%
Invested Capital Growth		 -9.61% -6.06% -1.05% 3.21% 1.41% -1.77% -2.79% -2.03% 0.26% 100.12% 99.68%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 20.30% 62.94% 7.92% 7.99% -40.49% 15.02% 66.74% 32.00% -26.52% 238.72% -183.08%
EBIT Q/Q Growth		 20.29% 61.36% 11.57% 8.04% -40.41% 15.09% 66.74% 32.00% -26.52% 238.72% -183.08%
NOPAT Q/Q Growth		 20.30% 61.36% 11.57% 8.04% -40.37% 7.48% 64.09% 42.18% -26.52% 298.17% -158.16%
Net Income Q/Q Growth		 27.23% 62.93% 21.59% 7.24% -37.33% 11.65% 67.71% 32.47% -29.12% 11,130.55% -101.05%
EPS Q/Q Growth		 31.25% 93.94% -300.00% 12.50% -42.86% -342,880.00% 97.87% -49,300.00% -29.15% 10,395.61% -101.12%
Operating Cash Flow Q/Q Growth		 -16.52% 20.81% 51.68% 43.29% 15.42% -1.78% 4.32% 34.94% 48.01% -111.10% 45.24%
Free Cash Flow Firm Q/Q Growth		 -27.41% 19.80% -134.15% -368.50% 19.67% 81.31% 331.98% -19.57% -163.93% -10,592.35% -1.06%
Invested Capital Q/Q Growth		 -0.79% 2.84% 1.58% -0.44% -2.66% -0.29% 0.60% 0.31% -0.36% 100.12% -371.02%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.10% 96.49% 99.92% 0.00% 100.00% 100.00% 100.00% 0.00%
Interest Burden Percent		 112.51% 107.94% 95.72% 96.46% 97.87% 98.35% 0.00% 94.71% 96.66% 7,685.94% 0.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 62.20% 49.16% 39.39% 23.01% 14.55% 13.79% 11.59% 9.30% 6.20% -217.40% -213.92%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -87,884.09% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 62.20% 49.16% 39.39% 23.01% 14.55% 14.01% 11.71% 9.39% 6.26% -228.42% -224.91%
Return on Equity Simple (ROE_SIMPLE)		 55.06% 0.00% 33.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -9.38 -3.62 -3.20 -2.95 -4.14 -3.83 -1.37 -0.79 -1.01 1.99 -1.16
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -16.31% -7.90% -3.92% -4.75% -8.12% -8.37% -2.30% -3.79% -5.92% 2,060.99% -7.34%
Return On Investment Capital (ROIC_SIMPLE)		 7.49% 2.76% 2.40% 2.15% 2.89% 2.58% 0.95% 0.54% 0.69% 50.13% -159.13%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -13 -5.18 -4.58 -4.21 -5.91 -5.02 -1.67 -1.14 -1.44 1.99 -1.66
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -4.96 -4.57 -4.20 -5.91 -5.02 -1.67 -1.14 -1.44 1.99 -1.66
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.60 19.64
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.60 19.64
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.03
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,040.78% 3,040.68%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 59.67 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.01 0.00 -0.01 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 -0.01 0.00 -0.01 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.31 0.21 0.26 0.19 0.13 0.10 0.07 0.05 0.04 0.11 0.09
Leverage Ratio		 -0.40 -0.29 -0.34 -0.26 -0.17 -0.13 -0.10 -0.08 -0.05 -0.13 -0.10
Compound Leverage Factor		 -0.44 -0.32 -0.33 -0.25 -0.17 -0.13 0.00 -0.08 -0.05 -9.70 0.00
Debt to Total Capital		 -1.03% -0.10% -0.91% -0.87% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 -0.10% -0.10% -0.10% -0.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 -0.92% 0.00% -0.81% -0.76% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1.98% 0.00% -1.76% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% -3.04% 0.00% -1.79% 0.00% 39.34% 85.51%
Common Equity to Total Capital		 101.03% 100.10% 100.91% 100.87% 100.00% 103.04% 101.98% 101.79% 101.76% 60.66% 14.49%
Debt to EBITDA		 -0.02 0.00 -0.03 -0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.47 0.37 0.31 0.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.02 0.00 -0.03 -0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.03 0.00 -0.04 -0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.68 0.53 0.44 0.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.03 0.00 -0.04 -0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -16.55 -23.29 -31.41 -38.20 -72.09 -63.87 -83.32 -105.71 -128.72 -44.39 -62.35
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -1.59% -1.03% -0.92% -0.89% -5.07% -5.14%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.47 4.36 7.54 5.63 9.74 6.00 7.75 17.14 8.20 0.00 0.00
Quick Ratio		 2.25 3.68 6.69 5.06 9.25 4.98 6.86 15.07 7.48 0.00 0.00
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 4.09 4.90 -1.67 -7.84 -6.30 -1.18 2.73 2.20 -1.40 -150 -152
Operating Cash Flow to CapEx		 0.00% -110,166.67% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 1.96 6.95 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -6.00 -14.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -6.00 -14.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -154 -149 -147 -148 -152 -152 -151 -151 -151 0.18 -0.48
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -13 -8.53 -1.53 4.90 2.16 -2.65 -4.11 -2.99 0.40 152 151
Enterprise Value (EV)		 -19 -12 -4.64 -1.67 -0.57 4.00 10 12 12 11 13
Market Capitalization		 7.96 6.48 7.61 7.89 7.89 7.92 14 14 14 14 14
Book Value per Share		 ($2.88) ($2.41) ($2.48) ($2.54) ($2.63) ($2.72) ($2.71) ($1.96) ($1.98) $0.05 $0.01
Tangible Book Value per Share		 ($2.95) ($2.47) ($2.53) ($2.60) ($2.63) ($2.72) ($2.71) ($1.96) ($1.98) $0.05 $0.01
Total Capital		 -125 -131 -133 -137 -143 -144 -144 -145 -147 6.55 5.02
Total Debt		 1.29 0.13 1.21 1.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 1.16 0.00 1.08 1.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -27 -18 -12 -9.56 -8.46 -8.29 -6.69 -5.23 -4.47 -6.38 -5.50
Capital Expenditures (CapEx)		 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.67 -1.45 -0.16 -0.76 -0.47 0.05 -0.10 0.37 -0.17 0.72 0.56
Debt-free Net Working Capital (DFNWC)		 19 17 13 9.99 7.99 8.34 6.59 5.60 4.30 7.10 6.06
Net Working Capital (NWC)		 19 17 13 9.84 7.99 8.34 6.59 5.60 4.30 7.10 6.06
Net Nonoperating Expense (NNE)		 5.70 1.96 1.18 1.12 1.45 1.10 0.22 0.28 0.38 -151 0.45
Net Nonoperating Obligations (NNO)		 -27 -18 -12 -9.56 -8.46 -8.29 -6.69 -5.23 -4.47 -6.38 -5.50
Total Depreciation and Amortization (D&A)		 0.01 0.22 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.33) ($0.02) ($0.08) ($0.07) ($0.10) ($342.98) ($0.01) ($4.94) ($6.38) $656.86 ($7.38)
Adjusted Weighted Average Basic Shares Outstanding		 45.48M 44.55M 54.39M 54.39M 54.39M 54.63M 98.50M 98.62M 98.62M 98.62M 98.62M
Adjusted Diluted Earnings per Share		 ($0.33) ($0.02) ($0.08) ($0.07) ($0.10) ($342.98) ($0.01) ($4.94) ($6.38) $656.86 ($7.38)
Adjusted Weighted Average Diluted Shares Outstanding		 45.48M 44.55M 54.39M 54.39M 54.39M 54.63M 98.50M 98.62M 98.62M 98.62M 98.62M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 54.39M 44.55M 54.39M 54.39M 54.39M 75.46M 75.46M 75.46M 75.46M 75.46M 160.43M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.76 -3.62 -3.20 -2.95 -2.62 -3.83 -1.37 -0.79 -1.01 1.39 -1.16
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -6.42 -7.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -4.49 -5.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -6.42 -7.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -4.49 -5.15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Galera Therapeutics (NASDAQ: GRTX) continues to look like a company in severe financial distress. Over the last several years, the pattern has been consistent: no revenue, recurring operating losses, shrinking cash, and a balance sheet that has been propped up by large non-operating accounting items rather than business growth.

The most important takeaway for retail investors: Galera is still burning cash while generating no sales, and its equity position remains extremely weak. That makes the stock highly speculative and dependent on financing, restructuring, or a major business turnaround.

  • Q1 2026 cash on hand improved to $5.5 million from $4.5 million in Q3 2025, suggesting some short-term liquidity stabilization.
  • Operating cash burn improved versus prior periods, with Q1 2026 operating cash outflow of $875,000 compared with $1.46 million in Q2 2025 and $2.24 million in Q1 2025.
  • Operating expenses were lower in Q1 2026 than in the same quarter a year earlier, with total operating expenses of $1.655 million versus $1.963 million in Q1 2025.
  • Interest and investment income provided a small offset to losses in the latest quarter, helping reduce pre-tax pressure.
  • The company still reported zero revenue in every quarter shown, so there is no operating sales base yet.
  • R&D spending has fallen sharply from historical levels, which may reflect a leaner cost structure but also suggests limited active development spending.
  • The latest balance sheet shows very little in noncurrent assets, with total assets of only $6.164 million in Q1 2026.
  • Common equity remains positive on paper at $728,000 in Q1 2026, but it is extremely thin relative to liabilities and the company’s prior losses.
  • Q1 2026 net loss was $1.606 million, continuing a long streak of unprofitable quarters.
  • The company’s cash balance has fallen dramatically over time, down from $13.466 million in Q1 2024 to $5.5 million in Q1 2026.
  • Retained earnings remain deeply negative at ($308.92 million) in Q1 2026, reflecting massive historical losses.
  • Q3 2025 showed a reported negative common equity position of ($149.2 million), underscoring how fragile the balance sheet has been.
  • The company has relied at times on large one-off accounting or financing-related items, such as the unusual Q4 2025 income spike, which makes earnings quality difficult to assess.
  • Liabilities remain material relative to assets, with total liabilities of $1.141 million in Q1 2026 and much larger historical liability burdens in prior periods.
  • Basic EPS remains deeply negative in normal quarters, including $(7.38) in Q1 2026.

Looking at the trend over the last four years, Galera has moved from a company with meaningful cash reserves in 2024 to one with a much smaller balance sheet and continuing quarterly losses. Cash usage has improved somewhat recently, but the company is still not self-funding and does not have revenue to support its operations.

From an investor perspective, the main risks are dilution, restructuring, or further capital stress. Unless Galera can produce a meaningful commercial or clinical catalyst, the financial statements suggest a highly speculative situation rather than a stable turnaround story.

07/28/26 10:12 AM ETAI Generated. May Contain Errors.

Galera Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Galera Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Galera Therapeutics' net income appears to be on a downward trend, with a most recent value of $149.05 million in 2025, falling from -$51.93 million in 2019. The previous period was -$18.96 million in 2024.

Galera Therapeutics' total operating income in 2025 was -$2.54 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $2.54 million

Over the last 6 years, Galera Therapeutics' total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

Galera Therapeutics' total liabilities were at $645 thousand at the end of 2025, a 99.6% decrease from 2024, and a 97.6% decrease since 2018.

In the past 7 years, Galera Therapeutics' cash and equivalents has ranged from $4.27 million in 2022 to $19.86 million in 2021, and is currently $6.38 million as of their latest financial filing in 2025.

Over the last 6 years, Galera Therapeutics' book value per share changed from 2.81 in 2019 to 0.05 in 2025, a change of -98.1%.


Related Companies

Financial statements for NASDAQ:GRTX last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
SpaceX pays a 10X launch penalty
SpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...
Freedom Financial | Sponsoredtc pixel
What Elon told his top shareholders in Texas
Late last year, Elon Musk gathered top shareholders at Tesla's Texas Gigafactory to unveil a plan to double Am...
Banyan Hill Publishing | Sponsoredtc pixel
Write This Down: A.R.M.
A secretive project tied to Elon Musk, nicknamed ARM, has caught investors' attention. Musk has suggested it c...
Paradigm Press | Sponsoredtc pixel
This A.I Revenue Machine Is Growing.. (BNZI)
Banzai International (NASDAQ: BNZI) just completed its transformational ConnectAndSell acquisition, adding AI-...
Huge Alerts | Sponsoredtc pixel
A storm is coming
The U.S. dollar has sunk to near a four-year low, while the Bureau of Economic Analysis prepares a change to h...
Stansberry Research | Sponsoredtc pixel
They sold their house … for IPO shares.
Some Silicon Valley home sellers are reportedly asking for pre-IPO shares instead of cash, specifically in AI ...
Weiss Ratings | Sponsoredtc pixel
What Do Trump, Buffett, and Bezos Know That We Don't?
President Trump quietly redacted 750 White House files, then wrote a 300 million dollar check to a controversi...
Brownstone Research | Sponsoredtc pixel